Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia
Patrice Chevallier, Virginie Roland, Béatrice Mahé, Nadine Juge-Morineau, Viviane Dubruille, Thierry Guillaume, Stéphane Vigouroux, Philippe Moreau, Noël Milpied, Richard Garand, Herve Avet-Loiseau, JVolume:
29
Year:
2005
Language:
english
Pages:
5
DOI:
10.1016/j.leukres.2005.02.005
File:
PDF, 69 KB
english, 2005